Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
Interventions
Abemaciclib, Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions
Avelumab, Cetuximab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more
Conditions
Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
Interventions
Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, Selumetinib Sulfate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Basal Cell Carcinoma
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
22
States / cities
Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 17 more
Conditions
Uveal Melanoma
Interventions
AEB071, BYL719
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Miami, Florida • New York, New York
Conditions
Breast Cancer
Interventions
Capecitabine, Exemestane, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases, Stage IV Breast Cancer
Interventions
imiquimod, Abraxane, laboratory biomarker analysis, RNA analysis, immunoenzyme technique
Drug · Other · Genetic
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Melanoma
Interventions
ALS-357
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Study of ADI-PEG 20 in Patients With Advanced Melanoma

NCT00520299
Conditions
Metastatic Melanoma, Skin Cancer, Neoplasm
Interventions
ADI PEG 20
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Conditions
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Tarceva
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more
Conditions
Breast Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
215
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Infliximab, Placebo, Relatlimab, Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions
Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more
Conditions
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions
HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Bakersfield, California • La Jolla, California • Pasadena, California + 28 more
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more